Drugs / Camizestrant
Camizestrant
also known as
AZD9833 · AZ-14066724 · CAMIZESTRANT (AZD9833) · CPD 28 · ESTROGEN RECEPTOR ANTAGONIST 2
Other / unclassified targets ESR1 via depletion
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Etcamah | — | 2026-07-20 | europa.eu ↗ |
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06547164 | Aug 2024 → Aug 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05790304 | Feb 2023 → Feb 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05551897 | Oct → Dec 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05438303 | Jun → Dec 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05364255 | May → Jun 2022 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04818632 | Nov 2021 → Sep 2023 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04541433 | Sep 2020 → Jul 2022 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04546347 | Sep 2020 → Jan 2021 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03616587 | Oct 2018 → Sep 2024 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06188520 | Dec 2023 → Aug 2027 expected | estrogen-receptor positive breast cancer, ovarian serous adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04644068 | Nov 2020 → May 2027 expected | biliary tract cancer, breast cancer, cervical cancer, colorectal cancer +8 | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07427394 | May 2026 → Dec 2027 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT07195227 | Mar 2026 → Feb 2028 expected | hormone receptor-positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 2 | NCT04588298 | Nov 2020 → Jun 2023 | Her2-receptor negative breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04214288 | Apr 2020 → Aug 2022 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07647328 | Jun 2026 → Feb 2029 expected | breast carcinoma by gene expression profile | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05952557 | Oct 2023 → Mar 2030 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05774951 | Mar 2023 → Apr 2027 expected | breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT04964934 | Jun 2021 → Jun 2025 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04711252 | Jan 2021 → Aug 2026 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | AstraZeneca | Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer astrazeneca.com ↗ |
| 2026-06-02 | AstraZeneca | Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 trial astrazeneca.com ↗ |
| 2026-05-27 | AstraZeneca | US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data astrazeneca.com ↗ |
| 2026-05-22 | AstraZeneca | Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer astrazeneca.com ↗ |
| 2026-04-30 | AstraZeneca | Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer astrazeneca.com ↗ |
| 2025-06-01 | AstraZeneca | Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗ |
| 2025-02-26 | AstraZeneca | Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial astrazeneca.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camizestrant | “PURPOSE: SERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen...” PMID 41628308 ↗ Jan 202614“Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a...” PMID 39481395 ↗ Nov 2024 “Switching to camizestrant at ESR1 mutation emergence before disease progression” PMID 42442380 ↗ Jul 2026 “Camizestrant is also called AZD9833.” NCT04711252 ↗ |
| Known as | AZ-14066724 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650365 ↗ |
| Known as | AZD9833 | “Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .” NCT06380751 ↗ |
| Known as | CAMIZESTRANT (AZD9833) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650365 ↗ |
| Known as | CPD 28 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650365 ↗ |
| Known as | ESTROGEN RECEPTOR ANTAGONIST 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650365 ↗ |
| Action | Deplete | “Estrogen receptor alpha degrader” CHEMBL4650365 ↗ |
| Action | Inhibit | “CONCLUSIONS: Camizestrant is a next-generation oral selective ER antagonist and degrader (SERD) and pure ER antagonist with a tolerable safety profile.” PMID 38729567 ↗ May 2024 |
| Modality | Other / unclassified | “Oral SERD Molecule” NCT04644068 ↗ |
| Route | Oral | “AZD9833 tablets will be administered orally.” NCT04214288 ↗ |
| Target | ESR1 | “Estrogen receptor alpha degrader” CHEMBL4650365 ↗ |